-+ 0.00%
-+ 0.00%
-+ 0.00%

SUMITOMO PHARMA AMERICA ANNOUNCES ENZOMENIB (DSP-5336) RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF R/R KMT2A-REARRANGED ACUTE LEUKEMIA

Reuters·10/26/2026 12:00:09

Please log in to view news